Antifungal Drugs Market to Witness Remarkable Growth by 2027 | key players Bayer Healthcare, Sanofi-Aventis, Novartis

This market research report provides a comprehensive picture on “Antifungal Drugs Market”, from the global viewpoint, offering a forecast and statistic in terms of revenue during the forecast period. The report covers a descriptive analysis with detailed segmentation, complete research and development history, latest news and press releases. Furthermore, the study explains the future opportunities and a sketch of key players operating in the “Antifungal Drugs Market”.

The Global Antifungal Drugs market accounted to US$ 10,182.3 Mn in 2018 and is expected to grow at a CAGR of 3.2% during the forecast period 2019 – 2027, to account to US$ 13,524.2 Mn by 2027.

Asia Pacific is the fastest growing geographic market and it is expected to be the fastest revenue contributor throughout the forecast period. Asia Pacific is recognized as a developing market for the pharmaceutical. The growth is driven by that countries such as China, and India which are engaged in conducting several studies.

Get Sample Copy of the Report at – https://www.theinsightpartners.com/sample/TIPRE00003745/?utm_source=OpenPR&utm_medium=10271

Strategic Insights

Organic and inorganic growth strategies were observed in global Antifungal Drugs industry. The organic strategies which were conducted more compared to the inorganic strategies for the Antifungal Drugs. For instance, in November, 2017, Merck & Co., Inc. declared that the U.S. Food and Drug Administration (FDA) approved PREVYMIS (letermovir) to be uses as once-daily tablets for oral use and injection for intravenous infusion. Thus, the organic strategy has enabled the company to grow its business in the market.

Antifungal Drugs – MARKET SEGMENTATION

Global Antifungal Drugs Market – By Infection Type

Superficial Fungal Infection
Systemic Fungal Infection
Global Antifungal Drugs Market – By Drug Type

Echinocandins
Azoles
Polyenes
Allylamines
Others
Global Antifungal Drugs Market – By Therapeutic Indication

Aspergillosis
Dermatophytosis
Candidiasis
Others
Global Antifungal Drugs Market – By Dosage Form

Drugs
Ointment
Powder
Others
By Geography

North America
U.S.
Canada
Mexico
Europe
France
Germany
UK
Spain
Italy

Asia Pacific (APAC)
China
India
Japan
Australia
South Korea
Middle East & Africa (MEA)
Saudi Arabia
South Africa
UAE

South America (SAM)
Brazil
Argentina
Company Profiles

Pfizer Inc.
Sanofi S.A.
Gilead Sciences, Inc.
Merck And Co., Inc.
Scynexis Inc.
Novartis International AG
Abbott Laboratories
Bayer AG
Glenmark Pharmaceutical
Glaxosmithkline Plc.

Growing Pharmaceutical Industry in Developing Regions

The developing nations are incredibly diverse, and the diseases and health care problems they face are somewhat variable. Thus, the solutions are different and must be made to fit local circumstances. Emerging nations represent an excellent opportunity for the pharmaceutical industry. The emerging markets are expected to be the crucial factor for offering better and lucrative growth opportunities for the market players to expand their business and geographic reach.

The treatment for the fungal infections become more straightforward due to the help of the advancement in the technologies. Also, the healthcare expenditure has created lots of opportunities for the developing nations to provide better and more services and facilities to their people. Regions like Asia, the Middle East, and Africa are investing more in the healthcare sectors.

Avail Discount on this Report at

https://www.theinsightpartners.com/sample/TIPRE00003745/?utm_source=OpenPR&utm_medium=10271

Market Insights

Increasing Incidence of Cancers, HIV, and Hospital-Acquired Infections

The incidence of fungal infections due to numerous diseases has increased over the last few decades. Furthermore, bloodstream infection incidence is bimodal, with adult people and premature babies having the maximum risk. Cancer treatment using chemotherapy and radiation causes various changes in the body as they destruct cancer cells. Among the significant difference, one is that this treatment weakens the immune system that increases the chances of getting a fungal infection.

Many fungal infections are called opportunistic infections, as they generally affect people with weak immune systems. As HIV weakens the immune system, it is more prone to have some types of fungal infections, like coccidioidomycosis, histoplasmosis, cryptococcosis, and pneumocystis pneumonia (PCP).

According to data published by J. Fungi 2017, approximately 3,000,000 cases of chronic pulmonary aspergillosis, around 223,100 cases of cryptococcal meningitis among HIV/AIDs patients. And nearly 700,000 cases of invasive candidiasis, about 250,000 cases of invasive aspergillosis, approximately 100,000 cases of disseminated histoplasmosis, more than 10,000,000 cases of fungal asthma, and around 1,000,000 cases of fungal keratitis occur per annum.

Contact Us:
Call: +1-646-491-9876
Email: sales@theinsightpartners.com
Website: www.theinsightpartners.com

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

This release was published on openPR.